Business Wire

New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO ® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed in the pivotal HELP Study, in patients who received treatment for a mean duration of 19.7 (0-26.1) months.1, 2 The analyses will also be published in the November issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology.

The original Phase 3 HELP Study was conducted in 125 patients over 26 weeks making it the largest randomised, controlled prevention study in HAE, with the longest active treatment duration, to date.3 The ongoing HELP Study OLE is designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO and is expected to be completed in November 2019. These analyses included 109 rollover patients, who were originally evaluated in the HELP Study, and 103 eligible non-rollover patients who did not participate in the initial study but had experienced at least one attack in 12 weeks.1, 2, 4

Results from the HELP Study OLE showed that the safety profile of TAKHZYRO was consistent with the original findings from the HELP Study, with treatment-related treatment emergent adverse events (TEAEs) occurring in 50% of patients (n=106).2 In addition, TAKHZYRO 300 mg every 2 weeks reduced the rate of attacks, attacks requiring acute treatment, and moderate to severe attacks (secondary efficacy endpoints). The mean attack rate was reduced by 87% overall compared with baseline (N=212). Similarly there was an overall reduction of 92.6% in the rate of attacks requiring acute treatment (N=212) and 83.6% in the rate of moderate/severe attacks versus baseline (N=212).1 An exploratory analysis showed that the overall maximum attack-free period lasted ≥12 months in 58% of patients (n=209) and ≥6 months in 78% of patients (n=209) following the first regular treatment dose.1

“While the original HELP Study data has given us a strong understanding of how TAKHZYRO can prevent HAE attacks, the results of these analyses provide encouraging insight into its potential safety and efficacy over a longer duration,” said Marc A. Riedl, M.D., investigator in the HELP Study OLE and Professor of Medicine and Clinical Director, U.S. Hereditary Angioedema Association Center at the University of California, San Diego. “As HAE is a lifelong condition, the long-term efficacy and safety of prophylactic medications are important factors in developing individualized HAE management plans. The HELP Study OLE analyses are a positive step forward in understanding the long-term effects of TAKHZYRO, and we look forward to gathering and sharing additional data as the study progresses.”

In the study, TEAEs occurred in ~95% of patients (N=212) and were mostly mild or moderate in severity. The TEAEs related to treatment that were reported in more than 5% of patients are injection site pain (33.9% of rollover patients [n=37] and 42.7% of non-rollover patients [n=44]), injection site erythema (11.9% of rollover patients [n=13] and 15.5% of non-rollover patients [n=16]) and injection site bruising (4.6% of rollover patients [n=5] and 9.7% of non-rollover patients [n=10]).2

TEAEs of special interest were reported in eight (3.8%) patients; none were serious. Six (2.8%) patients discontinued from the study due to TEAEs, one of which was treatment related (injection site papules). No treatment related, serious TEAEs or deaths occurred. Anti-lanadelumab antibodies were detected in 21 (9.9%) patients, including six (2.8%) positive for neutralizing antibodies with no discernible clinical impact.2

“Recurrent and unpredictable attacks of swelling can be debilitating and impact those living with HAE in a number of ways,” said Donatello Crocetta, M.D., Global Medical Head, Rare Immunology Franchise, Chief Medical Office, Takeda. “Over the last 10 years, we have been committed to continuous innovation in HAE to help address patients’ unmet treatment needs. These findings build on our knowledge about HAE and are valuable in better understanding the benefits that preventive treatment with TAKHZYRO could bring to patients in the longer term.”

Details on the HELP Study OLE abstracts being presented are as follows:

  • Long-Term Efficacy of Lanadelumab: Interim Results from the HELP OLE Study Abstract #P1591
    • Friday, 8 November, 5:15-5:30pm
  • Long-Term Safety of Lanadelumab in Hereditary Angioedema (HAE): Interim Results From the HELP OLE Study Abstract #P1582
    • Friday, 8 November, 5:00-5:15pm
  • Long-Term Lanadelumab Treatment Improves Health-related Quality of Life: HELP OLE Study Interim Findings Abstract #P1564
    • Friday, 8 November, 4:30-4:45pm

About The HELP StudyOpen-label Extension
The HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE) is an evaluation of the long-term efficacy and safety of TAKHZYRO in hereditary angioedema (HAE) patients of at least 12 years of age and older. Two hundred and twelve patients received treatment with TAKHZYRO at the start of the OLE Study (109 rollover patients originally evaluated in the HELP Study and who continued into the OLE, and 103 eligible patients who did not participate in the HELP study but who had experienced at least one attack in 12 weeks). Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack. Non-rollover patients were treated with one 300 mg dose every two weeks, beginning on Day 0. One hundred and ninety-three participants completed at least 12 months of treatment and 27 participants completed at least 24 months of treatment.1, 2

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The swelling can be debilitating and painful.5, 6, 7 Attacks that obstruct the airways can cause asphyxiation and are potentially life threatening.6, 7 HAE affects an estimated 1 in 10,000 to 1 in 50,000 people worldwide. It is often under-recognized, under-diagnosed and under-treated.5, 8

About TAKHZYRO® (lanadelumab-flyo) Injection
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein and is indicated for prophylaxis to prevent HAE attacks in patients 12 years and older. TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks.9 TAKHZYRO is intended for self-administration or administration by a caregiver. The patient or caregiver should be trained by a healthcare professional.9

U.S. Indication and Important Safety Information
INDICATION
TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.9

IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions
have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.9

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.9

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.9

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.9

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For U.S. audiences, please see the full Prescribing Information including Medication Guide for TAKHZYRO®.

For EU audiences, please see the Summary of Product Characteristics (SmPC) for TAKHZYRO®.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com.

References


1 Riedl MA, Cicardi M, Hao J, et al; for the HELP OLE Study Investigators. Long-Term Efficacy of Lanadelumab: Interim Results from the HELP Open-Label Study. ACAAI 2019. Abstract #P159.
2 Johnston DT, Banerji A, Nurse C, et al; for the HELP OLE Study Investigators. Long-Term Safety of Lanadelumab in Hereditary Angioedema (HAE): Interim Results From the HELP OLE Study. ACAAI 2019. Abstract #P158.
3 Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
4 Lumry WR, Maurer M, Megerl M, et al; for the HELP OLE Study Investigators. Long-term Lanadelumab Treatment Improves Health-related Quality of Life: HELP Open-label Extension Study Interim Findings. ACAAI 2019. Abstract #P156.
5 Cicardi M, Bork K, Caballero T, et al; on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67(2):147-157.
6 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
7 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
8 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.
9 TAKHZYRO ® (lanadelumab) Summary of Product Characteristics.

Contact information

Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Emily Bunting
emily.bunting@takeda.com
+41 79 866 9703

Kasandra Carr
kasandra.carr@takeda.com
+ 1 571 274 0439

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Universal Peace Federation: 70 Years After the Korean War World Leaders Call for Peace at Online Rally of Hope24.11.2020 19:19:00 CETPress release

Millions of viewers tuned into hundreds of broadcast stations and gathered online to call for peace among and between nations at the third Rally of Hope sponsored by the Universal Peace Federation (UPF) in Korea on Sunday, Nov. 22. UPF was founded in 2005 by Rev. Dr. Sun Myung Moon and Dr. Hak Ja Han Moon and is an NGO in General Consultative Status with the United Nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005906/en/ Dr. Hak Ja Han Moon addresses live audience and online participants from all around the world at the Rally of Hope (Photo: Business Wire) Mrs. Moon announced two new projects: to set up Korean War memorials in those nations that do not yet have them and create an online registry of all those who sacrificed in any way to support Korea during its darkest hour. “All around the world, unforeseen and unexpected challenges are erupting in the realms of politics, economy and religion” she said. “We

Verimatrix Chief Revenue Officer Named to SportsPro OTT Summit Advisory Board24.11.2020 17:45:00 CETPress release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Lu Bolden, Chief Revenue Officer, was named to the SportsPro OTT Summit Advisory Board, the group that shapes one of world’s most prominent sports broadcasting annual events. The second annual event takes place December 2-3, 2020. Organized by SportsPro Media, this year’s virtual SportsPro OTT Summit is the preeminent venue for learning the latest in strategy, content and technology trends in the sports broadcasting market. The OTT Summit Advisory Board reads as a who’s who of the digital sports broadcasting realm, including executives from the UFC, NFL, MotoGP, Fox Sports, DAZN, PGA Tour, Canal+, Formula One, NBC Sports and the International Olympic Committee. Bolden brings to the group the needed expertise in how to easily deliver excellent fan experiences on any device while also securely scaling during popular live eve

ender diagnostics Receives FDA Notification for Rapid and Reliable COVID-19 Tests24.11.2020 15:41:00 CETPress release

The two ender COVID-19 tests received the FDA notification, marking the entry of the Swiss company into the US market. With the continued surge of COVID-19 cases in the US, the American subsidiary of ender diagnostics, ENDER DIAGNOSTICS NORTH AMERICA, is ready to deliver rapid and reliable COVID-19 testing kits to diagnostic laboratories wishing to increase their testing capacities. The company is proud to be actively contributing to successfully manage the pandemic. The ender products are highly accurate and fast, allowing laboratories to increase their throughput significantly. ender LAB and ender MASS arein-vitro diagnostic test kits based on a rapid molecular isothermal nucleic acid amplification technology. Both ender LAB and ender MASS are designed for use by laboratory professionals or trained operators on standard real-time PCR devices. For ender LAB, the result is provided within 30 minutes after the extraction of the viral RNA, which makes it significantly faster than typical

LBC Tank Terminals Holding Netherlands B.V. Announces Q1 FY21 Financial Results Conference Call24.11.2020 15:06:00 CETPress release

LBC Tank Terminals announced today that a conference call will be held to discuss the company’s financial results for Q1 FY21 which ended on 30 September 2020. The results will be published today, Tuesday 24 November 2020, followed by a conference call for all investors on Tuesday, 1 December 2020 at 16:00 (Central European Time) / 10:00 (Eastern Standard Time). Call details and copies of the financial statements will be made available on the Intralinks website. Investors of LBC Tank Terminals Holding Netherlands B.V. Senior Notes, due 2023, can request access to Intralinks by contacting investors@lbctt.com. LBC Tank Terminals LBC Tank Terminals, with its headquarter in Belgium, is an independent operator of midstream and downstream bulk liquid storage facilities for chemicals, oils and refined petroleum products currently owning and operating seven terminals located in Houston, Freeport, Baton Rouge, Antwerp and Rotterdam with combined storage capacity of 2.6 million m³, serving over

BentallGreenOak’s Global Real Estate Investment Platform Receives Top Accolades in the 2020 Global Real Estate Sustainability Benchmark (GRESB), Marking 10 Years of Leadership in ESG24.11.2020 15:00:00 CETPress release

BentallGreenOak (BGO) announced today that its global real estate investment platform has again achieved top global rankings in the annual Global Real Estate Sustainability Benchmark (GRESB). The 2020 rankings mark the 10th straight year of outstanding leadership in ESG worldwide for BGO. The firm’s increased focus on asset resilience as an important element in its investment management strategy for its clients has resulted in several BGO accounts being ranked 1st overall in the world out of 412 participants in GRESB’s Resilience Module. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005284/en/ The BGO Diversified US Property Fund continued its leadership streak from 2019, ranking 1st in the U.S. Diversified, Core peer group, 2nd overall in the Americas, Diversified sector and 4th globally for the Diversified, Non-listed, Core peer group. The Sun Life General Account scored its best result ever, placing 2nd in Canada a

Digital Storytelling Platform ALEXANDER Launches with All-Star Cast24.11.2020 15:00:00 CETPress release

Alexander is the digital home of original non-fiction stories from around the world. Bringing together some of the world’s most respected creative talent, Alexander’s feature stories are commissioned from acclaimed global authors and journalists and give unique access to fascinating places, cultures and people. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005565/en/ Using the Alexander mobile app, every original feature is presented in multiple storytelling dimensions—a commissioned written story, an audio performance and a super short film. The crafted film introduces the setting, teases the subject and sets the mood. Audiences then transition into the full story and can read, listen or move seamlessly via The Toggle, a proprietary text-to-audio functionality, between the written word and the audio performance. The convergence creates an immersive storytelling experience that meets the high expectations of discernin